Table 1. Characteristics of Patients with asHU and Gout.
| asHU (n=8) | Acute gout (0ULT*) (n=14) | Chronic gout (cULT) (n=18) | p value | Post hoc p value (acute vs. chronic gout) | Post hoc p value (asHU vs. total gout) | ||
|---|---|---|---|---|---|---|---|
| Male | 8 (100.0) | 14 (100.0) | 18 (100.0) | ||||
| Age (yr) | 56.5±12.9 | 49.7±15.8 | 50.0±17.4 | 0.413 | 0.962 | 0.298 | |
| Height (cm) | 171.5±4.9 | 172.8±4.8 | 174.6±7.9 | 0.230 | 0.456 | 0.364 | |
| Body weight (kg) | 76.0±13.8 | 74.2±8.5 | 80.9±14.9 | 0.263 | 0.158 | 0.697 | |
| BMI (kg/m2) | 25.7±3.5 | 24.8±2.4 | 26.6±5.2 | 0.473 | 0.230 | 0.939 | |
| 18.5–23 | 1 (12.5) | 3 (23.1) | 4 (23.5) | 0.443 | 0.233 | 0.638 | |
| ≥23 | 4 (50.0) | 5 (38.5) | 3 (17.6) | ||||
| ≥25 | 2 (25.0) | 5 (38.5) | 6 (35.3) | ||||
| ≥30 | 1 (12.5) | 0 (0.0) | 4 (23.5) | ||||
| Comorbidities | |||||||
| Hypertension | 0 (0.0) | 4 (28.6) | 7 (38.9) | 0.122 | 0.815 | 0.080 | |
| Dyslipidemia | 0 (0.0) | 3 (21.4) | 7 (38.9) | 0.100 | 0.501 | 0.165 | |
| Diabetes | 0 (0.0) | 0 (0.0) | 1 (5.6) | 0.534 | 0.999 | 0.999 | |
| CKD | 0 (0.0) | 1 (7.1) | 13 (72.2) | 0.001 | 0.001 | 0.034 | |
| Risk factors for gout | |||||||
| Protein/alcohol intake | 2 (25.0) | 10 (71.4) | 8 (44.4) | 0.091 | 0.243 | 0.236 | |
| Familyhistory of gout | 0 (0.0) | 2 (14.3) | 1 (5.6) | 0.433 | 0.819 | 0.881 | |
| Disease duration of gout | NA | 1.0±1.4 | 41.4±36.8 | NA | 0.001 | NA | |
| Laboratory findings | |||||||
| Total bilirubin (mg/dL) | 0.6±0.2 | 0.8±0.3 | 0.8±0.2 | 0.110 | 0.878 | 0.036 | |
| AST (IU/L) | 33.6±14.3 | 26.9±8.5 | 29.3±10.9 | 0.523 | 0.490 | 0.216 | |
| ALT (IU/L) | 26.9±5.2 | 28.6±17.3 | 31.8±20.9 | 0.477 | 0.649 | 0.363 | |
| ALP (IU/L) | 79.1±21.9 | 74.9±18.5 | 80.1±31.9 | 0.827 | 0.592 | 0.896 | |
| TG (mg/dL) | 285.5±57.7 | 266.4±127.5 | 220.0±134.9 | 0.303 | 0.443 | 0.515 | |
| Glucose (mg/dL) | 100.0±6.8 | 97.5±14.4 | 107.7±23.2 | 0.232 | 0.206 | 0.403 | |
| LDL-cholesterol (mg/dL) | 135.1±17.6 | 134.0±37.7 | 132.1±32.4 | 0.866 | 0.907 | 0.909 | |
| HbA1c (%) | 5.5±0.3 | 5.5±0.5 | 5.6±0.1 | 0.694 | 0.673 | 0.886 | |
| ESR (mm/h) | 12.7±13.5 | 24.7±26.8 | 16.6±12.7 | 0.660 | 0.538 | 0.335 | |
| CRP (mg/L) | 1.5±1.3 | 9.1±14.6 | 4.5±5.4 | 0.471 | 0.518 | 0.078 | |
| BUN (mg/dL) | 13.8±3.5 | 17.3±7.3 | 17.5±6.0 | 0.202 | 0.925 | 0.134 | |
| Uric acid (mg/dL) | 8.2±1.3 | 8.8±1.6 | 6.0±2.7 | 0.006 | 0.002 | 0.156 | |
| Creatinine(mg/dL) | 0.9±0.1 | 1.1±0.3 | 1.1±0.2 | 0.068 | 0.784 | 0.001 | |
| Creatinine clearance (mL/min/1.73 m2) | 92.8±12.9 | 83.5±26.2 | 80.3±22.9 | 0.220 | 0.718 | 0.220 | |
| ULT | 0.001 | 0.099 | 0.001 | ||||
| Allopurinol, n (%) | 0 (0.0) | 5 (45.5) | 2 (11.1) | ||||
| Febuxostat, n (%) | 0 (0.0) | 6 (54.5) | 16 (88.9) | ||||
Data are shown in mean±standard deviation or n (%).
*Only baseline characteristics were obtained from acute gout patients before ULT.
BMI, body mass index; CKD, chronic kidney disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; TG, triglyceride; LDL, low-density lipoprotein; BUN, blood urea nitrogen; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ULT, uric acid-lowering therapy; NA, not applicable; asHU, asymptomatic hyperuricemia; 0ULT, acute gout patients before ULT; cULT, chronic gout patients after ≥6-month ULT.